Session Details

[Pe-005]English Poster Session 005 Parkinson's disease (Biomarker and others)

Wed. May 21, 2025 5:20 PM - 6:40 PM JST
Wed. May 21, 2025 8:20 AM - 9:40 AM UTC
ポスター会場(大阪国際会議場3F イベントホール)
Chairs: Takahiko Tokuda(Osaka Metropolitan University, Japan), Hirohisa Watanabe(Department of Neurology, Fujita Health University, School of Medicine, Japan)

[Pe-005-1]Diagnostic Accuracy of Skin Alpha-synuclein Assays in Parkinson's Disease: A Meta-analysis

Yang Zhao1,2, Kai Li1,2, Yunchuang Sun1,2, Mingyue Luan1,2, Jing Liu1,2, Qingqing Wang1,2, Jianwen Deng1,2, Zhaoxia Wang1,2 (1.Department of Neurology, Peking University First Hospital, China, 2.Beijing Key Laboratory of Neurovascular Disease Discovery, China)

[Pe-005-2]Characteristics of visual attention during natural viewing in Parkinson's disease

Takashi Uematsu1, Takashi Tsuboi1, Keita Hiraga1, Daigo Tamakoshi1, Taiki Fukushima1, Maki Sato1, Shuning Han2, Zhe Sun2, Takashi Michikawa2, Hideo Yokota2, Masahisa Katsuno1 (1.Department of Neurology, Nagoya University Graduate School of Medicine, Japan, 2.RIKEN Center for Advanced Photonics Image Processing Research Team, Japan)

[Pe-005-3]Serum Cholinesterase as a Marker of Nutritional Disorders Tied to Weight Loss in Parkinson's Disease

Atsuhiro Higashi1, Reiko Ohdake1, Yasuhiro Maeda2, Ami Narimoto1, Yusuke Mizuno1, Akira Satou1, Syunsuke Adachi1, Konoka Kanda1, Yuji Tsujimura1, Yousuke Kouno1, Shoko Ri1, Kazutaka Hayashi1, Kunihisa Katoh1, Toshiki Maeda1, Ryunosuke Nagao1, Seiko Hirota1, Sayuri Shima1, Yasuaki Mizutani1, Akihiro Ueda1, Mizuki Itoh1, Hirohisa Watanabe1 (1.Department of Neurology, Fujita Health University School of Medicine, Japan, 2.Fujita health University Open Facility Center, Japan)

[Pe-005-4]Plasma NfL/GFAP index differentiates early Parkinson disease from elderly, MCI and Alzheimer disease

Akira Yokote1, Ken-ichiro Yamashita1,2, Tomohiro Imamura2,3, Atsushi Ohno4, Guzailiayi Maimaitijiang2, Yuki Yanagihara1,2, Keiko Haro1,2, Ayako Sakoda1,2, Yuri Nakamura1,2,3, Tomo Iura5, Yasuhiro Maeda5, Mari Shinoda5, Kaoru Yagita5, Nobutaka Sakae6, Naokazu Sasagasako6, Motohiro Yukitake7, Yasuhiko Baba8, Masakazu Hashimoto4, Noriko Isobe5, Jun-ichi Kira1,2,3,4 (1.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, Japan, 2.Translational Neuroscience Research Center, Graduate School of Medicine, International University of Health and Welfare, Japan, 3.Department of Pharmaceutical Sciences, School of Pharmacy at Fukuoka, International University of Health and Welfare, Japan, 4.Platform Technology Research Unit, Drug Research Division, Sumitomo Pharma Co., Ltd., Japan, 5.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 6.Department of Neurology, National Hospital Organization, Omuta Hospital, Japan, 7.Department of Neurology, Kouhoukai Takagi Hospital, International University of Health and Welfare, Japan, 8.Department of Neurology, Faculty of Medicine, Fukuoka University, Japan)

[Pe-005-5]CSF YKL-40 level predicts the cognitive progress of de novo Parkinson's disease

Ma Junyi (Shandong First Medical University, China)